Exchange: NASDAQ·Updated 07:56 PM EST

EDIT News

News
all
press releases
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Zacks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Zacks
More News
Editas (EDIT) delivered earnings and revenue surprises of +28.57% and +498.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of -10.98% and -28.36%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Under the FDA’s new draft guidance, companies can file one application that covers several versions of the same gene-editing treatment, as long as each version aims to make the same kind of genetic correction.
Stocktwits
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Zacks
In studies on non-human primates, EDIT-401 reduced bad cholesterol and other harmful blood fats by around 90%.
Stocktwits
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Stocktwits
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...
Benzinga
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.read more...
Benzinga
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks

Advertisement|Remove ads.